论文部分内容阅读
溴隐亭(Bromocriptin)是治疗垂体泌乳激素腺瘤(Prolactinoma)和生长激素腺瘤(G H adeno-ma)的药物之一。为探讨溴隐亭对瘤细胞形态变化的影响和临床应用价值,我们对五例服用溴隐亭四周以上,手术切除的PRL腺瘤(Prolactinoma)进行了电镜观察,並与未用药的PRL腺瘤进行了比较,发现:1.瘤细胞超徽结构的变化主要表现在瘤细胞变小,核变小,核仁减小或消失,染色质溶解。粗面内质网明显扩张迂曲,囊腔内有电子密度低的絮状物聚集,膜面上核糖体减少或消失。高尔基体扁平囊扩张,线粒体嵴减少或消失,出现空泡化。这些变化可导致瘤细胞的物质代谢和能量代谢障碍,使PRL和GH等蛋白类激素的合成受影响,致使血中的激素水平降低。
Bromocriptin is one of the drugs for the treatment of pituitary prolactinoma and GH adeno-ma. To investigate the effect of bromocriptine on the morphological changes of tumor cells and its clinical application value, we performed electron microscopic observation of five cases of PRL adenoma (Prolactinoma) that had been treated with bromocriptine for more than four weeks, and compared with untreated PRL adenomas. Comparisons were made and it was found that: 1. The changes of the supercellular structure of the tumor cells are mainly manifested in the small tumor cells, small nuclear changes, diminished or disappeared nucleoli, and chromatin dissolution. The rough endoplasmic reticulum significantly expands and curls, and flocs with low electron density accumulate in the cyst cavity, and the ribosomes on the membrane surface decrease or disappear. Golgi’s flat sac expands, mitochondrial ridges decrease or disappear, and vacuolation occurs. These changes can lead to material metabolism and energy metabolism disorders of tumor cells, affecting the synthesis of PRL and GH and other protein hormones, resulting in lower blood hormone levels.